• Mashup Score: 0
    Uncovering the Immunoregulatory Function and Therapeutic Potential of the PD-1/PD-L1 Axis in Cancer - 3 year(s) ago

    Immune checkpoint blockade involves the targeted antagonism of immunosuppressive interactions between antigen-presenting cells and/or tumor cells and effector T cells. Blockade of B7-H1, also known as programmed death-ligand 1 (PD-L1), prevents the ligation of inhibitory PD-L1 molecules to programmed cell death receptor 1 (PD-1) on T cells, engendering a potentiated response of tumor-specific T…

    Source: Cancer Research
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CR_AACR
      CR_AACR

      Work by Hirano et al generated scientific rationales for a new generation of cancer treatment that targets the PD-1/PD-L1 signaling pathway in the tumor microenvironment. Pitter and Zou discuss this landmark discovery in their #CRLandmarks commentary. https://t.co/JPZ7dTqEhi https://t.co/X4oCnkKO9F